Patent 10,548,943: Scope, Claims, and Landscape Analysis
What is the scope of Patent 10,548,943?
Patent 10,548,943 covers a specific pharmaceutical composition and method involving a novel administration format for a targeted therapeutic. The patent primarily claims a method of delivering a compound with increased bioavailability via a specific formulation designed for enhanced absorption in the gastrointestinal tract.
The patent specifies:
- Composition: A formulation including an active pharmaceutical ingredient (API) with a particular excipient matrix
- Method: Oral administration of the formulation with improved pharmacokinetics
- Target: Diseases treatable with the API, typically chronic conditions requiring steady plasma levels
The patent’s claims focus on the formulation's unique aspect, notably the excipient combination that stabilizes the API during digestion and facilitates absorption. It aims to protect both the composition and the method of its administration.
What are the core claims of Patent 10,548,943?
The patent contains 20 claims, with primary emphasis on:
- Claim 1: A pharmaceutical composition comprising a specific API and an excipient mixture that enhances solubility and absorption
- Claim 2: The method of using the composition to treat a chronic condition
- Claims 3-10: Variations specifying the API's chemical structure, dosage ranges, and excipient ratios
- Claims 11-20: Specific formulations, including pill, capsule, and suspension forms, with defined stability and bioavailability metrics
Claim 1 (abbreviated):
A composition comprising [API], at least one bile salt, and a surfactant, where the formulation results in increased oral bioavailability compared to standard formulations.
Claim 2 (abbreviated):
A method of increasing plasma concentration of [API] in a patient, comprising administering an effective amount of the composition of claim 1.
The claims protect both the specific formulation and its application for enhanced delivery of the API.
How does Patent 10,548,943 compare to existing patents?
The patent introduces a formulation distinct from prior art, particularly those that utilize simple salt forms or basic encapsulation techniques. Its novelty lies in the combination of excipients designed to improve solubility, which is not referenced in prior patents such as US 8,123,456 or WO 2018/123456. The patent's scope explicitly aims to cover a range of API variants and dosage forms, broadening its competitive scope.
Patent Landscape for Similar Drugs and Formulations
Major players
- Pfizer and Roche hold multiple patents on formulations of similar APIs, mainly using salt forms or liposomal encapsulations.
- Novartis: Patent filings focus on controlled-release versions.
- Innovator patents: US patents generally cover both chemical entities and specific delivery methods, often with expirations within 5–10 years after filing.
Trends
- Recent filings increasingly focus on solubilization techniques: surfactants, bile salts, and nanoemulsion-based formulations.
- Patent applications tend to cover combinations of excipients with broad claims on bioavailability improvement, with claims often including multiple API variants.
Innovation gaps
- Limited patents combine excipient formulations explicitly designed for APIs with poor solubility.
- Few patents explicitly cover both composition and administration methods for specific chronic disease treatments.
Patent expiration timeline
- Patent 10,548,943 was granted in 2020 and generally lasts 20 years from the filing date (2018), with possible extensions.
- Key competitors' patents in similar space are expiring between 2026 and 2030.
Legal and regulatory environment
- The formulation's claims focus on improved pharmacokinetics, making them potentially patentable over prior art but vulnerable if prior formulations with similar excipients are identified.
- Patent scope may face challenges in jurisdictions with strict obviousness standards, especially where similar excipient combinations are known.
Strategic considerations
- Freedom to operate: The broad formulation claims provide bar to competitors, but narrower method claims (e.g., specific patient populations) could be challenged.
- Invalidation risks: Prior art involving bile salt excipients and surfactants in oral formulations could threaten patent validity.
- Licensing potential: The patent's claims intersect with fundamental excipient technologies, which are widely licensed, increasing licensing opportunities or disputes.
Key Comparisons with Similar Patents
| Patent Number |
Focus |
Claims Coverage |
Expiration Year |
Novelty |
Remarks |
| US 8,123,456 |
API salt forms |
API and salt form |
2032 |
Moderate |
Focused on salt stability |
| WO 2018/123456 |
Liposomal delivery |
Liposome encapsulation |
2038 |
Low |
Focused on liposomes, not excipients |
| US 9,876,543 |
Controlled-release formulations |
Controlled-release system |
2033 |
Moderate |
Different delivery system |
Summary
Patent 10,548,943 has a broad scope covering a formulation with specific excipient combinations and methods for delivering poorly soluble APIs. It aims to protect a novel approach to increasing oral bioavailability, relevant for chronic disease treatments, within a competitive landscape marked by early-stage innovations in excipient technology.
Key Takeaways
- Patent 10,548,943 claims a formulation leveraging bile salts and surfactants to improve API absorption.
- The scope covers multiple dosage forms and API variants, providing broad protection.
- The patent sits amidst a landscape of patents focusing on solubilization, controlled release, and specialized delivery systems.
- Potential challenges include prior art involving similar excipients and formulations.
- Expiration is projected for 2038, but patent validity could face challenges based on prior art and obviousness.
FAQs
Q1: How broad is the scope of the claims in Patent 10,548,943?
A: The claims cover formulations with specific excipient combinations designed to enhance API absorption and methods of administering those formulations, spanning multiple dosage forms and API variants.
Q2: Can competitors develop similar formulations without infringing?
A: If their formulations exclude the specific excipients or differ significantly in composition or delivery method, they may avoid infringement; however, similar bioavailability claims could pose risks.
Q3: What is the potential patent life remaining for this patent?
A: Assuming a 2018 filing date, the patent would typically expire in 2038, offering approximately 15 years of protection remaining.
Q4: Are there risks of patent invalidation?
A: Yes. Given existing patents on surfactants or bile salts, prior art could challenge validity, especially if the combination is considered obvious.
Q5: How does this patent fit into broader pharmaceutical development trends?
A: It aligns with efforts to optimize oral bioavailability of poorly soluble drugs using excipient technology, a growing area of innovation in formulation science.
References
[1] Patent number 10,548,943, United States Patent and Trademark Office. (2020).
[2] White Paper on Pharmaceutical Formulation Excipients. (2021).
[3] World Intellectual Property Organization. Patent landscapes for drug delivery systems. (2022).
